Trial Profile
An Expanded Access Program of Carmeseal-MD (P-188 NF) outside of the United States
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 15 Sep 2017
Price :
$35
*
At a glance
- Drugs Poloxamer 188 (Primary)
- Indications Heart failure
- Focus Expanded access; Therapeutic Use
- 15 Sep 2017 New trial record
- 13 Sep 2017 According to a Phrixus Pharmaceuticals media release, the company is about to treat first patient with Carmeseal-MD (P-188 NF) outside of the United States.